Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements (Details)

v2.4.1.9
Collaborative, Licensing and Other Arrangements (Details)
12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2014
License Arrangement [Member]
License
Dec. 31, 2014
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Oct. 31, 2011
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 1 [Member]
USD ($)
Dec. 31, 2014
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2013
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2010
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2009
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Sep. 30, 2008
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 2 [Member]
USD ($)
Dec. 31, 2014
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Dec. 31, 2012
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Jul. 31, 2006
National Institute of Allergy and Infectious Diseases "NIAID" [Member]
Arrangement with Governmental Agency 3 [Member]
USD ($)
Dec. 31, 2007
Pfizer Inc. [Member]
License Arrangement [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Jan. 31, 2011
Collaborative Arrangement [Member]
Servier [Member]
EUR (€)
Dec. 31, 2014
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Servier [Member]
USD ($)
Dec. 31, 2014
Collaborative Arrangement [Member]
Servier [Member]
Sales And Development Milestones [Member]
USD ($)
Sep. 30, 2010
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
USD ($)
Dec. 31, 2014
Collaborative Arrangement [Member]
Servier - U.S. Perindopril Franchise [Member]
Product
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Dec. 31, 2014
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2012
Collaborative Arrangement [Member]
Takeda [Member]
USD ($)
Dec. 31, 2014
Collaborative Arrangement [Member]
Takeda [Member]
Development Milestone [Member]
USD ($)
Feb. 28, 2009
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Nov. 30, 2006
Collaborative Arrangement [Member]
Takeda [Member]
Sales Milestone [Member]
USD ($)
Jan. 31, 2014
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Dec. 31, 2014
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Dec. 31, 2013
Collaborative Arrangement [Member]
Novartis [Member]
USD ($)
Nov. 30, 2008
Collaborative Arrangement [Member]
Novartis [Member]
Development Milestone [Member]
USD ($)
Product
Dec. 31, 2014
Collaborative Arrangement [Member]
Pfizer Inc. [Member]
Sales Milestone [Member]
USD ($)
Dec. 31, 2012
Non-arrangement Transactions [Member]
Pfizer Inc. [Member]
Development Milestone [Member]
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                                                                  
Non-refundable upfront payment received                                     $ 15,000,000xoma_ProceedsFromUpfrontPaymentReceived
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                           
Period for recognizing deferred revenue                                         8 months                                        
Proceeds from loan                                     19,500,000us-gaap_ProceedsFromIssuanceOfDebt
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
15,000,000us-gaap_ProceedsFromIssuanceOfDebt
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                         
Total contract amount awarded               28,000,000us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency1Member
          64,800,000us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
    16,300,000us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
                                               
Contractual term         5 years       3 years           3 years                                                    
Deferred revenue 1,939,000us-gaap_DeferredRevenueNoncurrent 4,105,000us-gaap_DeferredRevenueNoncurrent                         1,900,000us-gaap_DeferredRevenueNoncurrent
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
                                                   
Increase (decrease) in deferred revenue                       900,000us-gaap_DeferredRevenuePeriodIncreaseDecrease
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
1,100,000us-gaap_DeferredRevenuePeriodIncreaseDecrease
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
  (1,800,000)us-gaap_DeferredRevenuePeriodIncreaseDecrease
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
2,000,000us-gaap_DeferredRevenuePeriodIncreaseDecrease
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
                                                 
Recognition of deferred revenue         8,400,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency1Member
4,700,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency1Member
2,500,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency1Member
  1,200,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
4,400,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
6,600,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency2Member
        2,000,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
                        1,600,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
100,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
1,200,000us-gaap_RecognitionOfDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                   
Remaining deferred revenue                             100,000xoma_RemainingDeferredRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty2Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= xoma_NonsoftwareLicenseArrangementWithGovernmentalAgency3Member
                                                   
Future initial research and development expenses to be funded by counterparty                                         50,000,000xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterpartyUnderCollaborativeArrangement
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                       
Future other expenses to be funded by counterparty (in hundredths)                                         50.00%xoma_OtherExpenseFundedThroughCollaborativeArrangementPercentage
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                       
Licensing and collaboration agreement revenue 5,683,000us-gaap_LicenseAndServicesRevenue 11,028,000us-gaap_LicenseAndServicesRevenue 5,727,000us-gaap_LicenseAndServicesRevenue                                   3,500,000us-gaap_LicenseAndServicesRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
13,600,000us-gaap_LicenseAndServicesRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
14,500,000us-gaap_LicenseAndServicesRevenue
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                   
Future milestone payments, maximum                                               433,000,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_SalesAndDevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                3,250,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_SalesMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
19,000,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_SalesMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
        14,000,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_DevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Future milestone payments, repurchase option not exercised, maximum                                               770,000,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentRightsNotReacquired
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_SalesAndDevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty1Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                                 
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier                                                   3xoma_NumberOfFixedDoseCombinationProductCandidatesIncludedInPortfolioOfAntihypertensiveProductsFromServier
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty13Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                             
License fees paid                                                 1,500,000xoma_LicenseFeeAmountPaid
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty13Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                               
Future milestone payments with each additional future qualifying product candidate development, maximum                                                               20,750,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentWithEachAdditionalFutureQualifyingProductCandidateDevelopment
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_DevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty4Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
                1,700,000xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentWithEachAdditionalFutureQualifyingProductCandidateDevelopment
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_DevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty12Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_NonarrangementTransactionsMember
Royalty right expiration period                                                     10 years 13 years 6 months               20 years          
Proceeds from collaborators                                                                       6,200,000us-gaap_ProceedsFromCollaborators
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
         
Reduction in debt under restructured agreement                                                                       7,500,000us-gaap_DebtInstrumentDecreaseForgiveness
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
         
Number of ongoing product programs with potential royalty right milestone payments                                                                             2xoma_NumberOfOngoingProductProgramsWithPotentialRoyaltyRightMilestonePayments
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_DevelopmentMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
   
Maximum borrowing capacity under agreement                                                                         50,000,000xoma_DebtInstrumentMaximumBorrowingCapacity
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
       
Research and development expenses funded through loan facility, maximum (in hundredths)                                                                         75.00%xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
       
Additional future milestone payments                                                                               17,900,000xoma_CollaborativeArrangementContingentConsiderationAdditionalPotentialCashPayment
/ us-gaap_ContingentConsiderationByTypeAxis
= xoma_SalesMilestoneMember
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty12Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
 
Number of licenses granted, minimum       60xoma_NumberOfLicensesGrantedMinimum
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_NonsoftwareLicenseArrangementMember
                                                                         
Proceeds from license fees received                                   30,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty12Member
/ us-gaap_DeferredRevenueArrangementTypeAxis
= us-gaap_NonsoftwareLicenseArrangementMember
                                             
Percentage of milestone received                                                                     25.00%xoma_PercentageOfMilestoneReceived
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
           
Milestone received under the collaboration agreement                                                                           7,000,000xoma_MilestoneReceivedUnderCollaborationAgreement
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
     
Repayment of debt                                                                     $ 1,750,000xoma_LongTermDebtMaturitiesRepayment
/ xoma_DeferredRevenueArrangementNameOfPartyAxis
= xoma_DeferredRevenueArrangementNameOfParty5Member
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember
           
Euro to US Dollar exchange rates 1.216us-gaap_ForeignCurrencyExchangeRateTranslation1